ClinicalTrials.gg
Active, not recruitingNCT05764213Updated Oct 20, 2026

Improving Maternal Mental Health & SUD Screening and Treatment

An interventional study of Listening to Women & Pregnant and Postpartum People in Mental Health Issue, Substance Use Disorders and Postpartum Depression, sponsored by Medical University of South Carolina. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Screening

How we know

Updated Oct 20, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10,469
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Substance-Related Disorders by Medical University of South Carolina — 6 open to participants now, 9 under way, none of them phase 3. Substance-Related Disorders · Medical University of South Carolina.

Enrollment
Largest of 47
10,469 · median 81
Started
2023
with 1 other
No phase
24 of 48
5 open now
Registered
39th of 48
by date

Among the 48 studies in Substance-Related Disorders by Medical University of South Carolina, this one has the largest enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2023, is one of 24 with no phase, and was the 39th registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

6 of the 48 studies in Substance-Related Disorders by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Substance-Related Disorders by Medical University of South Carolina, or all of them as a file.
02

Study summary

The purpose of the study is to compare a text message-based mental health and substance use screening and referral to a treatment program, called Listening to Women and Pregnant and Postpartum People (LTWP), to standard of care in-person mental health and substance use screening to look at rates of treatment attendance and retention in treatment. Participation would involve completing online questionnaires. You may be eligible to participate if you are age 18-45 years, are pregnant and entering prenatal care in one of MUSC's OB clinics, and attended a prenatal appointment at an MUSC clinic.

Read the detailed description

Aim 1: To determine differences in rates of treatment attendance and retention for Perinatal Mood and Anxiety Disorders (PMADs) and Perinatal Substance Use Disorders (PSUDs) between participants assigned to LTWP, compared to SBIRT.

Aim 2: To determine differences in Patient-Reported Outcomes (PROs) including depressive symptoms, quality of life, substance use, and maternal functioning and well-being measured at baseline and 2, 5, 8, and 11 months postpartum.

03

Conditions studied

  • Mental Health Issue
  • Substance Use Disorders
  • Postpartum Depression
  • Postpartum Anxiety
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Aim 1:

This study is a cluster RCT step wedge design so we are randomizing on the clinic level, not the individual level. The clinics are made up of 4 "wedges" (3 clinics/wedge). Pregnant women receiving prenatal care in these clinics will receive SBIRT as part of usual care. Clusters of clinics will be randomized to an LTWP start date where they will transition from SBIRT to LTWP for the purposes of screening and referral to treatment.

EHR Data Collection (PPP):

Inclusion:

  1. Age 18-45
  2. pregnant and entering prenatal care in one of MUSC's OB clinics
  3. attended a prenatal appointment at an MUSC clinic

Exclusion:

a.) primary language is not English or Spanish

Aim 2:

Study Assessments at baseline and 2, 5, 8, and 11 months postpartum (PPP):

Inclusion:

  1. Age 18-45 years
  2. pregnant
  3. attended an initial prenatal appointment at an MUSC OB clinic

Exclusion:

  1. Unable to complete study assessments
  2. primary language is not English or Spanish
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10,469 participants (actual)

Study arms

  • No intervention
    Screening Brief Intervention & Referral to Treatment (SBIRT)

    This group will receive in-person screening and referral to treatment assessment.

  • Experimental
    Listening to Women & Pregnant & Postpartum People (LTWP)

    This group will receive text-message-based SBIRT with phone-based assessment and referral to treatment. The SBIRT is a survey with 9 questions related to depression, anxiety, substance abuse (alcohol, cigarettes, and other drugs including prescription medication), and domestic violence.

    Behavioral: Listening to Women & Pregnant and Postpartum People

Interventions

  • BehavioralListening to Women & Pregnant and Postpartum People

    Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, home-based telemedicine mental health and substance use disorder treatment services.

06

What researchers measure

Primary outcomes

  1. Change in Treatment Attendance

    Treatment attendance is defined as attending at least 1 or more visits with a mental health or substance use disorder treatment provider.

    Time frame: Through participants baseline prenatal care appointment and pregnancy and the postpartum year for participants, approximately 21 months

  2. Change in Retention in Treatment

    Retention in treatment for PMADs: defined as 6 or more psychotherapy visits and/or 4 or more medication management visits; and PSUDs: are defined as continuous pharmacological and/or behavioral treatment \> 2 months.

    Time frame: Through participants baseline prenatal care appointment and pregnancy and the postpartum year for participants, approximately 21 months

Secondary outcomes

  1. Change in depressive symptoms

    We will compare the mean change in the Edinburgh Postnatal Depression Scale (EPDS) among those assigned to LTWP compared to SBIRT. A score of 10 or more on the EPDS suggests clinically elevated depressive symptoms requiring further evaluation. A higher score on the EPDS is a worse outcome.

    Time frame: Change from baseline depression screening symptoms to follow-up depression screening symptoms during the postpartum year, approximately over 21 months.

  2. Change in Substance Use

    We will compare the change in substance use frequency and amount as measured by the ASSIST among those assigned to LTWP compared to SBIRT. A score of 0-3 (0-4 for cannabis) has an indicated response for brief education, a score of 4-26 (5-26 for cannabis) has an indicated response for brief intervention, a score of 27+ has an indicated response for brief intervention (offer options that include treatment).

    Time frame: Change from baseline substance use to follow-up substance use during the postpartum year, approximately over 21 months.

  3. Change in Maternal Functioning and Wellbeing

    We will compare the change in maternal functioning measured by the Barkin Index of Maternal Functioning among those assigned to LTWP compared to SBIRT. Each item is rated on a 7-point likert scale ranging from 0 = "strongly disagree" to 6 = "strongly agree". The total score ranges from 0 to 120. Higher levels of functioning are associated with higher total scores with 120 representing optimal functioning. Lower levels of functioning are associated with lower scores.

    Time frame: Change from baseline maternal functioning to follow-up maternal functioning during the postpartum year, approximately over 21 months.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jul 2027, 51 months after the start.

Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 51 months is above that.

Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2023
First posted
Mar 10, 2023
StartActual
Apr 3, 2023
Primary completionEst.
Jul 31, 2027
CompletionEst.
Oct 1, 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
10470→10469
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Enrollment 10470→10469
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05764213
Collaborators
Patient-Centered Outcomes Research Institute
Responsible party
Constance Guille (Professor, Medical University of South Carolina) — Principal investigator
First posted
Mar 10, 2023
Start date
Apr 3, 2023
Primary completion
Jul 31, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Constance Guille, MD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion